EU/3/04/208: Orphan designation for the treatment of polycythaemia vera

acetylsalicylic acid

Table of contents

Overview

On 29 July 2004, orphan designation (EU/3/04/208) was granted by the European Commission to Bayer Vital GmbH, Germany, for acetylsalicylic acid for the treatment of polycythemia vera.

Key facts

Active substance
acetylsalicylic acid
Intended use
Treatment of polycythaemia vera
Orphan designation status
Positive
EU designation number
EU/3/04/208
Date of designation
29/07/2004
Sponsor
Bayer Vital GmbH
Welserstr. 5-7
D-51149 Köln
Germany
Tel. +49 2203 56 82 53
Fax +49 2203 56 83 73
E-mail: Marianne.Petersen-Braun@bayerhealthcare.com

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating